TX-ZILLIANT
Zilliant , the industry leader in intelligent B2B price optimization, price management and sales guidance software, today introduced the Real-Time Pricing Engine™, a new product that enables business-to-business (B2B) companies to calculate and deliver prices in real-time to any commercial system.
Executing pricing logic and delivering prices in real-time to digital commerce channels is often beyond the capabilities of many companies’ existing pricing engines. The Zilliant Real-Time Pricing Engine™ meets the growing need for a faster, more robust way of handling the pricing demands of complex omnichannel B2B companies. The solution’s high-availability, high-performance REST API with 99.99% guaranteed uptime instantaneously executes complex pricing logic, and performs complex calculations, including external data lookups, to deliver prices to any ERP, CRM, CPQ, eCommerce platform or mobile application.
“We set out to help customers power intelligent commerce in the digital age, and the Real-Time Pricing Engine™ is one of the most effective tools to accomplish that,” said Zilliant President and Chief Executive Officer Greg Peters. “Companies seeking to be more dynamic in their approach to pricing are no longer constrained by the limitations of legacy systems. With real-time pricing, they can execute complex pricing calculations in milliseconds.”
The Rise of B2B Digital Commerce Calls for Real-Time Pricing
Gartner has mentioned pricing as one of the core functional components of a commerce platform. In the report, “Harness the Core Capabilities of a Digital Commerce Platform ,” Gartner states pricing “may need to be real-time if pricing is highly dynamic. Real-time integrations to ERP are fraught with performance risks, so often, caching layers or other forms of ERP protection must be in place. [The] interaction of pricing with promotional engines can be complex and must be approached with caution. Pricing management is an area of growing sophistication and disruption. Third-party point solutions are often required to take advantage of innovations.”1
“36% of B2B buyers say an inability to get the best price online is a significant barrier to doing more business via the digital commerce channel,” stated Gartner Senior Research Director, Mark Lewis in a report.2 “To unblock those potential buyers, it’s essential to employ an AI-driven, real-time and value-based pricing engine, which can consider competition, customer profile, stock availability, etc. to come up with the best price for each buying situation. Not all customers have to see the same prices. This model is employed successfully to optimize the profits of airlines, hotels and car rental companies. In this situation, customers must understand that they are seeing a spot price that can go up or down. Most importantly, they must get the same spot price regardless of channel interaction.”2
Zilliant Real-Time Pricing Engine™ ─ in conjunction with Zilliant Price Manager™ ─ meets the need for a third-party point solution to effectively manage and house pricing logic and reliably calculate and deliver the correct price for a customer in real-time. In practice, each transaction or quote request triggers a complex pricing build or look up to determine the right price, along with its attendant taxes, fees and discounts. Further, the proliferation of scenarios that require on-demand pricing is vast; it’s not uncommon for tens of thousands of pricing requests to flow through a company in various channels daily. Companies can significantly increase the speed, accuracy and consistency of pricing – as well as the pricing negotiation process – by using the Real-Time Pricing Engine™ and Price Manager™ to automate negotiations, counteroffers and approvals based on pre-defined parameters.
Learn more about real-time pricing and the Zilliant Real-Time Pricing Engine™ .
1 Gartner, “Harness the Core Capabilities of a Digital Commerce Platform,” Mike Lowndes, Christina Klock, published September 4, 2019 and refreshed on February 9, 2021.
2 Gartner, “Increase Profits and Delight Buyers by Becoming a Digital-First, Omnichannel B2B Seller,” Mark Lewis, April 1, 2021.
Gartner Disclaimer:
GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Zilliant
Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005137/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
